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Mechanisms of α-Synuclein Induced
Synaptopathy in Parkinson’s Disease
Jessika C. Bridi and Frank Hirth*
King’s College London, Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute,
Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom
Parkinson’s disease (PD) is characterized by intracellular inclusions of aggregated
and misfolded α-Synuclein (α-Syn), and the loss of dopaminergic (DA) neurons in
the brain. The resulting motor abnormalities mark the progression of PD, while
non-motor symptoms can already be identified during early, prodromal stages of disease.
Recent studies provide evidence that during this early prodromal phase, synaptic
and axonal abnormalities occur before the degenerative loss of neuronal cell bodies.
These early phenotypes can be attributed to synaptic accumulation of toxic α-Syn.
Under physiological conditions, α-Syn functions in its native conformation as a soluble
monomer. However, PD patient brains are characterized by intracellular inclusions of
insoluble fibrils. Yet, oligomers and protofibrils of α-Syn have been identified to be
the most toxic species, with their accumulation at presynaptic terminals affecting
several steps of neurotransmitter release. First, high levels of α-Syn alter the size
of synaptic vesicle pools and impair their trafficking. Second, α-Syn overexpression
can either misregulate or redistribute proteins of the presynaptic SNARE complex.
This leads to deficient tethering, docking, priming and fusion of synaptic vesicles at
the active zone (AZ). Third, α-Syn inclusions are found within the presynaptic AZ,
accompanied by a decrease in AZ protein levels. Furthermore, α-Syn overexpression
reduces the endocytic retrieval of synaptic vesicle membranes during vesicle recycling.
These presynaptic alterations mediated by accumulation of α-Syn, together impair
neurotransmitter exocytosis and neuronal communication. Although α-Syn is expressed
throughout the brain and enriched at presynaptic terminals, DA neurons are the most
vulnerable in PD, likely because α-Syn directly regulates dopamine levels. Indeed,
evidence suggests that α-Syn is a negative modulator of dopamine by inhibiting enzymes
responsible for its synthesis. In addition, α-Syn is able to interact with and reduce
the activity of VMAT2 and DAT. The resulting dysregulation of dopamine levels directly
contributes to the formation of toxic α-Syn oligomers. Together these data suggest a
vicious cycle of accumulating α-Syn and deregulated dopamine that triggers synaptic
dysfunction and impaired neuronal communication, ultimately causing synaptopathy and
progressive neurodegeneration in Parkinson’s disease.
Keywords: Parkinson’s disease, synapse, SNARE complex, active zone, dopamine, α-synuclein, synaptopathy,
neurodegeneration
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INTRODUCTION
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder after Alzheimer’s disease (AD)
(Kalia and Lang, 2015). The pathological hallmarks of PD
are intracellular proteinaceous inclusions called Lewy bodies
(LB) and Lewy neurites (LN) that are predominantly formed
of misfolded and aggregated forms of the presynaptic protein
α-Synuclein (α-Syn), and the loss of dopaminergic (DA) neurons
in the substantia nigra (SN) (Spillantini et al., 1997; Lang
and Lozano, 1998a,b). Loss of DA neurons in the SN leads to
marked decrease of dopamine levels in synaptic terminals of the
dorsal striatum (Figures 1A,B), ultimately leading to a loss of
the nigrostriatal pathway (Cheng et al., 2010). The reduction
of striatal dopamine triggers a range of motor symptoms
including bradykinesia, uncontrollable tremor at rest, postural
impairment, and rigidity which together characterize PD as a
movement disorder.
The onset of PD, however, is considered to commence
at least 20 years prior to detectable motor abnormalities,
when a variety of non-motor symptoms can be observed
(Hawkes et al., 2010; Kalia and Lang, 2015; Mahlknecht et al.,
2015). This period is referred to as the prodromal phase
where patients experience a range of non-motor symptoms
FIGURE 1 | Midbrain dopaminergic neurons are specifically vulnerable in Parkinson’s disease. (A) The predominant symptoms of Parkinson’s disease (PD) are caused
by loss of dopaminergic (DA) neurons in the substantia nigra (SN). According to the dying-back hypothesis, the degeneration of DA neurons is preceded by
dysfunction and in turn degeneration of the nigrostriatal pathway, which innervates the caudate nucleus and the putamen that together form the striatum. (B)
Compared to healthy controls (left), nigrostriatal degeneration results in the depletion and ultimate loss of the neurotransmitter dopamine on synaptic terminals of
striatal neurons (right). (C) The resulting motor symptoms, among others, are usually diagnosed when approximately 30–60% of striatal DA neurons are already lost.
However, PD patients can experience non-motors symptoms 20 years before the onset of motor abnormalities in the so-called prodromal phase; these include
olfactory dysfunction, sleep disturbances and depression.
including constipation, olfactory dysfunction (hyposmia), sleep
disturbance, obesity and depression (Figure 1C; Hawkes et al.,
2010; Kalia and Lang, 2015; Mahlknecht et al., 2015). During
the prodromal phase of PD and PD-related disorders, which
precedes degenerative cell loss, the expression levels of a range
of proteins involved in synaptic transmission are altered in
the prefrontal and cingulate cortex, and SN (Dijkstra et al.,
2015; Bereczki et al., 2016; Table 1), suggesting that both non-
motor and motor symptoms are caused by impaired synaptic
communication. This data indicates that neurodegeneration in
PD is a dying back-like phenomenon which starts at synaptic
terminals in the striatum and progresses along the nigrostriatal
pathway, ultimately affecting homeostasis and survival of DA cell
bodies in the SN (Hornykiewicz, 1998; Calo et al., 2016; Caminiti
et al., 2017). It is due to these early-onset synaptic alterations
observed prior to DA neuron loss, PD has also been classified as
a synaptopathy (Brose et al., 2010; Schirinzi et al., 2016).
The majority of PD cases are sporadic with unknown cause.
However, familial cases with autosomal dominant or recessive
Mendelian inheritance have revealed fundamental insights into
pathogenic mechanisms underlying PD (Keane et al., 2011;
Massano and Bhatia, 2012; Kalia and Lang, 2015). The most
commonly identified genetic mutations linked to heritable PD
were found in the genes SNCA and LRRK2, responsible for
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TABLE 1 | Alterations of presynaptic proteins seen with α-Syn related proteinopathy in PD and DLB patients and rodent animal models.
Protein Modification Species Assay system References
Synapsin 1 Down Human Post-mortem tissue from DLB patients Scott et al., 2010
Rat BAC rat model overexpressing the full-length human SNCA Kohl et al., 2016
Mouse Hippocampal neurons overexpressing human WT α-Syn:GFP Scott et al., 2010
Mouse Overexpression of human WT α-Syn Nemani et al., 2010
Synapsin 2 Down Human Post-mortem tissue from PD patients (Braak stages 1–2) Dijkstra et al., 2015
Mouse Overexpression of human WT α-Syn Nemani et al., 2010
Mouse Primary neuronal culture treated with α-Syn pre-formed fibrils Volpicelli-Daley et al., 2011
Synapsin 3 Down Human iPSCs from patients harboring A53T mutation Kouroupi et al., 2017
Up Human Post-mortem tissue from PD patients (Braak stages 1–2) Dijkstra et al., 2015
Synaptophysin Down Human Post-mortem tissue from DLB patients Kramer and Schulz-Schaeffer,
2007
Mouse Overexpression of human α-Syn under the mThy1 promoter Games et al., 2014
Up Human Post-mortem tissue from PD patients (Braak stages 1–2) Dijkstra et al., 2015
CSPα Down Mouse Primary neuronal culture treated with α-Syn pre-formed fibrils Volpicelli-Daley et al., 2011
SV glycoprotein 2 Down Human iPSCs from patients harboring A53T mutation Kouroupi et al., 2017
Rab3A/Rab3 Down Human iPSCs from patients harboring A53T mutation Kouroupi et al., 2017
Human Post-mortem tissue from PDD and DLB patients Bereczki et al., 2016
Rat Nigral injection of AAV2-A53T-α-Syn Chung et al., 2009
Mouse Overexpression of human WT α-Syn Nemani et al., 2010
VAMP-2 Down Mouse Hippocampal neurons overexpressing human WT α-Syn:GFP Scott et al., 2010
Mouse Primary neuronal culture treated with α-Syn pre-formed fibrils Volpicelli-Daley et al., 2011
Misloc. Human Post-mortem tissue from PD patients (striatum-putamen and
external globus pallidus)
Garcia-Reitböck et al., 2010
Up Mouse Truncated human α-Syn Garcia-Reitböck et al., 2010
Mouse Overexpression of human WT α-Syn Nemani et al., 2010
SNAP-25 Down Human Post-mortem tissue from PDD and DLB patients Bereczki et al., 2016
Mouse Primary neuronal culture treated with α-Syn pre-formed fibrils Volpicelli-Daley et al., 2011
Misloc. Human Post-mortem tissue from PD patients (striatum-putamen and
external globus pallidus)
Garcia-Reitböck et al., 2010
Mouse Truncated human α-Syn Garcia-Reitböck et al., 2010
Up Mouse Overexpression of human WT α-Syn Nemani et al., 2010
Syntaxin-1/Syntaxin Down Human Post-mortem tissue from DLB patients Kramer and Schulz-Schaeffer,
2007
Rat Nigral injection of AAV2-A53T-α-Syn Chung et al., 2009
Mouse Overexpression of human WT α-Syn Nemani et al., 2010
Misloc. Human Post-mortem tissue from PD patients (striatum-putamen and
external globus pallidus)
Garcia-Reitböck et al., 2010
Mouse Truncated human α-Syn Garcia-Reitböck et al., 2010
Synaptotagmin 1 Up Mouse Overexpression of human WT α-Syn Nemani et al., 2010
Synaptotagmin 2 Up Human Post-mortem tissue from PD patients (Braak stages 1–2) Dijkstra et al., 2015
Complexin 1 Down Mouse Overexpression of human WT α-Syn Nemani et al., 2010
Complexin 2 Down Human Post-mortem tissue from PD patients (Braak stages 1–2) Dijkstra et al., 2015
Mouse Overexpression of human WT α-Syn Nemani et al., 2010
Synphilin 1 Down Human Post-mortem tissue from PD patients (Braak stages 1–2) Dijkstra et al., 2015
Munc18-1 Up Mouse Overexpression of human WT α-Syn Nemani et al., 2010
Munc13-1 Down Mouse Overexpression of human WT α-Syn Nemani et al., 2010
Piccolo Down Mouse Hippocampal neurons overexpressing human WT α-Syn:GFP Scott et al., 2010
RIM3 Down Rat BAC rat model overexpressing the full-length human SNCA Kohl et al., 2016
Amphiphysin Down Mouse Hippocampal neurons overexpressing human WT α-Syn:GFP Scott et al., 2010
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an autosomal-dominant forms of PD, and in Parkin, PINK1,
DJ-1, and ATP13A2 which account for PD with autosomal
recessive mode of inheritance (Klein and Westenberger, 2012;
Ferreira and Massano, 2017). PD-related mutations in PINK1
and Parkin and the functional interaction of the two proteins led
to the identification of mitochondrial dysfunction as one of the
major pathogenic pathways underlying PD (reviewed in Exner
et al., 2012; Pickrell and Youle, 2015). Additionally, PD-related
mutations in Glucocerebrosidase (GBA), SCARB2 and ATP13A2
established lysosomal storage dysfunction as a second pathogenic
pathway that also contributes to PD etiology (reviewed in Hardy,
2010; Gan-Or et al., 2015).
However, among the identified PD-related genes, SNCA
encoding the presynaptic protein α-Syn remains the most
potent culprit underlying PD. Accumulated α-Syn is the main
component of LB, and together with genome-wide association
studies it has been shown to have central pathogenic role in
both familial and sporadic PD (Satake et al., 2009; Simón-
Sánchez et al., 2009). Yet despite recent progress, the pathogenic
mechanisms underlying α-Syn related PD are only starting to
emerge. Here we provide a focussed review emphasizing current
knowledge on synaptic function and the various mechanisms of
α-Syn induced synaptopathy, and its role in the early stages of PD
progression.
ACCUMULATION OF α-SYNUCLEIN: THE
PATHOLOGICAL HALLMARK OF PD
α-Syn is a small soluble cytoplasmic protein of 140 amino
acid; its main protein domains comprise an amphipathic region,
non-amyloid-β component (NAC) domain and an acidic tail
(Figure 2A; Maries et al., 2003; Venda et al., 2010). α-Syn
together with β-Syn and γ-Syn belong to the synuclein protein
family (Goedert, 2001; Marques and Outeiro, 2012). The three
Synuclein proteins are 55–62% identical in sequence and have
similar domain organization (Goedert, 2001); all three are highly
expressed in the human brain (Goedert, 2001). Additionally,
α-Syn and β-Syn share the same subcellular distribution at
presynaptic terminals in neurons (Jakes et al., 1994; Goedert,
2001). However, α-Syn is the only protein of the synuclein family
to be found in LB and to be implicated in PD pathogenesis
(Goedert et al., 2017).
Several dominant-inherited single point mutations in SNCA
gene have been identified in families that develop early onset
PD (Polymeropoulos, 1997; Krüger et al., 1998; Zarranz et al.,
2004; Appel-Cresswell et al., 2013; Lesage et al., 2013; Pasanen
et al., 2014). Subsequent studies identified multiplications of the
SNCA gene locus (Singleton, 2003; Farrer et al., 2004) and SNCA
polymorphisms which are associated with high risk of developing
the disease (Satake et al., 2009; Simón-Sánchez et al., 2009). In
line with dosage-related α-Syn pathology, higher doses of α-
Syn observed in patients with duplication and triplication of the
SNCA gene locus directly correlate with cognitive decline, motor
and non-motor symptoms and severity of neurodegenerative
phenotypes (Venda et al., 2010). This data is strong evidence
that dysfunction and accumulation of α-Syn plays a key role
in both familial and sporadic forms of PD. In addition to LB
inclusions, α-Syn has been shown to accumulate in axons (Braak
et al., 1999) and in the presynaptic terminal (Kramer and Schulz-
Schaeffer, 2007), suggesting these pathogenic accumulations are
a key trigger of onset and formation of PD-related synaptopathy
(Stefanis, 2012; Schirinzi et al., 2016) (Box 1).
In the healthy brain and central nervous system (CNS), wild
type α-Syn is available in its native conformation as soluble
monomers. These are thought to mediate its physiological
FIGURE 2 | The presynaptic protein α-Synuclein is a pathological seed for Parkinson’s disease formation. (A) α-Synuclein (α-Syn) is a small soluble cytoplasmic
protein of 140 amino acid encoded by the SNCA gene; its main protein domains comprise an N-terminal amphipathic region, a non-amyloid-β component (NAC)
domain and a C-terminal acidic tail. Several dominant inherited missense mutations have been identified in the amphipathic region causing early-onset PD, whereas
the NAC domain has been implicated in α-Syn aggregation. (B) Under normal physiological conditions, α-Syn monomers function in a dynamic equilibrium between a
soluble and a membrane-bound state. Under cellular stress and in disease-relation conditions, α-Syn monomers can interact leading to oligomers that buffer the
formation of protofibrils, ultimately causing the formation of amyloid-β sheet fibrils that aggregate into Lewy bodies (LB).
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BOX 1 | α-Syn-mediated synaptopathy - open questions and future directions.
Progress over the past two decades revealed compelling evidence that one of the major sites of α-Syn-mediated toxicity are presynaptic terminals. Once initiated, the
resulting neuronal dysfunction can lead to both cell intrinsic and cell-extrinsic toxicity. Cell-intrinsic mechanisms cause axonal degeneration which progresses toward
the cell body, eventually leading to dying-back like neurodegeneration. Cell-extrinsic mechanisms cause transmission of α-Syn oligomers along synaptic connections
and the ultimate progression of synucleopathy throughout the patient brain. Neither of these mechanisms are fully understood, nor how α-Syn oligomerizes in the
first place, thus precluding the development of efficient therapeutic treatments. To progress toward therapy, several open questions need to be addressed.
Conformational changes of α-Syn
α-Syn accumulates in synapses and axons and forms neuronal inclusions. What triggers α-Syn self-assembly and in turn the formation of toxic species of misfolded
α-Syn? How do different types of oligomers serve as template for fibril formation of α-Syn? There is evidence that the formation of fibrils, rather than toxic species
themselves, mediates α-Syn toxicity (Lashuel et al., 2013). Which aspect of this process is so pathogenic to neurons? It also remains to be shown whether α-Syn
may form various types of oligomeric states with different toxicity. To address these questions in a systematic way, first and foremost reliable markers are required to
monitor, both in vitro and in vivo, the different and progressive conformational changes of α-Syn and their impact on toxicity.
α-Syn acts as a chaperone for the presynaptic SNARE complex. It controls assembly, maintenance and distribution of this highly reactive complex of proteins. Can
this environment be responsible for triggering the pathologic cascade to form α-Syn oligomers and fibrils? The increased stability and longer half-life of mutant forms
of α-Syn, such as A30P and A53T, increase their potential of aggregation (Bennett et al., 1999; Cuervo et al., 2004). In addition, failure of proteasomal degradation
and autophagy in PD have been linked to high levels of α-Syn. Together, these factors can favor the accumulation of pathologic α-Syn. Small molecule and compound
screens together with in vivo genetic screens in animal models are necessary to identify mechanisms and molecules that can abrogate, hamper or at least delay
misfolding of α-Syn, and thus progression of disease.
Accumulation of α-Syn and synaptic defects
What is the threshold concentration of toxic α-Syn species, such as oligomers and fibrils, to trigger biochemical and cellular alteration that lead to neuronal dysfunction?
Oligomeric forms of α-Syn are considered the most toxic species at the synapses (Ingelsson, 2016) and their structure appears different between mutant forms and
wild type α-Syn (Tosatto et al., 2015). This suggests the severity of pathology may not only relate to the abundance and formation of oligomers but also to their
structural and functional properties. It remains to be shown whether distinct oligomeric α-Syn species, and their way of formation, exert differential toxic mechanisms
that specifically impair the presynaptic terminal and neurotransmission.
Do oligomeric and fibrils of α-Syn cause a dominant negative effect in synaptic function? Can α-Syn oligomers, for instance, reduce the activity of its synaptic partners
and neuronal signaling pathways? The effect of different lengths and concentrations of α-Syn oligomers on SNARE-mediated membrane fusion and docking are one
way to measure toxicity, as previously shown in vitro (Choi et al., 2013; Lai et al., 2014). In vitro protein-reconstituted systems are necessary to test the effects of
different toxic α-Syn species on fast Ca2+-triggered neurotransmitter release and their in vivo toxicity in synaptic transmission.
α-Syn transmission and transcellular progression of disease
Several studies using animal models have given strength to Braak’s hypothesis for α-Syn propagation within interconnected brain regions (reviewed in Oueslati et al.,
2014). However, the mechanisms underlying α-Syn transmission remain poorly understood. Which α-Syn toxic species are “seeding” for trans-synaptic transmission?
What is the minimum concentration of toxic α-Syn required to trigger transmission? Can extracellular α-Syn and exosomes be efficiently cleared by pharmacological or
gene therapy approaches without affecting the intracellular endogenous α-Syn? To address these questions, in vivo systems to allow monitoring of α-Syn transmission
are required. For example, Drosophila melanogaster has been successfully used to study transcellular spreading of human huntingtin (Htt) (Babcock and Ganetzky,
2015). This model system has opened avenues for unbiased whole genome screening of cellular mechanisms and pharmacological interventions of Htt transmission.
α-Syn transmissibility could also be studied in brain organoids derived from induced pluripotent stem cells (iPSCs) of healthy individuals and patients harboring
α-Syn mutations. Although an in vitro culture, organoids resemble the in vivo architecture, functionality, and genetic signature of original tissues (Dutta et al., 2017).
Moreover, organoids develop neuronal networks that can be modulated by sensory stimulation (Quadrato et al., 2017). Hence organoids can be used to study α-Syn
propagation along interconnected neuronal networks.
function in presynaptic terminals (Burré, 2015). Although LB are
characterized by β-sheet aggregated fibrils of α-Syn (Spillantini
et al., 1997; Rodriguez et al., 2015), in vitro studies have shown
that the formation of oligomers, not fibrills, are a distinct
hallmark of α-Syn mutations such as A30P and A53T, which
are known to cause early-onset familial PD (Conway et al.,
2000). The NAC domain of α-Syn is a hydrophobic sequence
formed of 12 amino acids which forms the core part of the
α-Syn protein and is key for its transformation from soluble
monomer to oligomers, into protofibrils and finally aggregating
fibrils (Figure 2B; Giasson et al., 2001). In vitro studies performed
by Narhi and colleagues demonstrated that wild type, as well
as mutant A30P and A53T α-Syn can form insoluble β-
sheet structured fibrillar aggregates at physiological temperature
(Narhi et al., 1999). Importantly, mutant forms of α-Syn promote
fibril formation more rapidly than the wild type α-Syn protein.
The carriers of A30P and A53T α-Syn point mutations are also
more prone to α-Syn aggregation and toxicity, hence correlating
with increased vulnerability and earlier onset of PD formation in
SCNAmutant carriers (Li et al., 2001; Ingelsson, 2016).
Aggregated and oligomeric α-Syn are also implicated in prion-
like transmission of progressive PD pathology along distant but
connected brain regions (Spillantini et al., 1997; Jucker and
Walker, 2013). The accumulation of α-Syn in LB undergo an
ascending pattern of distribution, from the lower brainstem
and olfactory bulb into the limbic system and ultimately to
the neocortex (Braak et al., 2003). Several hypotheses attempt
to address the cellular mechanisms underlying progressive α-
Syn transmission spreading throughout these brain regions
(Longhena et al., 2017). Few studies have supported that cell-
to-cell transmissibility of α-Syn occurs at the synapses, through
physiological processes such as exocytosis and endocytosis or due
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to synaptic degeneration (Frost and Diamond, 2009; Guo and
Lee, 2014). Although the underlyingmechanisms so far remained
elusive, there is strong evidence that progressive transmission
correlates with severity of the disease (Hawkes et al., 2010)
(Box 1).
WHERE DOES PD PATHOLOGY START?
Several neurodegenerative diseases exhibit early impairment
of synaptic function (Bae and Kim, 2017). This often occurs
concomitantly with the manifestation of cognitive symptoms,
with a neuronal degeneration emerging at later stages of
disease (Milnerwood and Raymond, 2010; Schulz-Schaeffer,
2010; Picconi et al., 2012). Thus, synaptic dysfunction is
considered to be the first step followed by active deconstruction
of axons and loss of neuronal connectivity, eventually leading
to the death of neuronal perikarya (Figure 3; Scott et al., 2010;
Lu et al., 2014; Morales et al., 2015; Schulz-Schaeffer, 2015; Calo
et al., 2016; Grosch et al., 2016; Tagliaferro and Burke, 2016; Bae
and Kim, 2017; Fang et al., 2017; Kouroupi et al., 2017; Roy,
2017). This succession of events suggests that neural death in
PD is initiated at synaptic terminals and progresses proximally
toward neural cell bodies in a dying back-like manner.
In line with this hypothesis, almost 20 years ago Hornykiewicz
suggested that formation of PD starts by affecting axons in
the dorsal striatum prior to degeneration of DA neurons in
the SN (Hornykiewicz, 1998). However, this hypothesis only
recently gained strong support by a range of pathological and
FIGURE 3 | α-Syn accumulation in presynaptic terminals causes synaptopathy ultimately leading to dying back-like neurodegeneration. (A) Under physiological
conditions, α-Syn functions as monomers at the presynaptic terminals in synaptic transmission. (B) Formation of toxic α-Syn species, such as oligomers and fibrils,
have been shown to play a pivotal role in PD pathogenesis. These toxic species accumulate at the presynaptic terminal, leading to altered levels of proteins involved in
synaptic transmission, ultimately causing synaptic dysfunction. (C) As a result of toxic α-Syn accumulation, affected synapses will undergo a process of active
deconstruction leading to loss of neuronal connections and subsequent death of the neuronal perikarya.
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molecular data. The first evidence that axons were affected in
PD came from the pioneer study performed by Braak et al.
(1999). They were able to demonstrate that extensive and very
thin α-Syn inclusions were not only present in LB inclusions
at the neuron soma but also present in axonal processes
(Braak et al., 1999). More recent studies found α-Syn localized
within axonal dystrophic neurites in the striatum of patients
with Alzheimer’s disease (AD) and PD (Duda et al., 2002),
as well as in multiple system atrophy (MSA) and dementia
with Lewy body (DLB) (Galvin et al., 1999). The localization
of α-Syn was further studied through the development of a
technique called paraffin-embedded tissue (Kramer and Schulz-
Schaeffer, 2007). This method allowed for the detection of
abundant α-Syn micro-aggregates in the neuropil rather than
in the cell body of DLB patient brains. Furthermore, Kramer
and Schulz-Schaeffer showed the abundance of synaptic α-
Syn micro-aggregates exceeded the amount of α-Syn aggregates
in LB or LN by one to two orders of magnitude. Their
filtration technique revealed 50–92% of α-Syn micro-aggregates
were found entrapped within the presynaptic terminal. This
result correlated with the striking downregulation of presynaptic
proteins like syntaxin and synaptophysin, and postsynaptic
proteins such as PSD95 and drebrin (Kramer and Schulz-
Schaeffer, 2007).
This new mechanistic insight exploring synaptic deficits as a
starting point in α-Syn related pathology is in agreement with
previous findings, where α-Syn aggregates were observed in axon
terminals preceding the formation of LB in DLB and correlating
with cognitive impairment (Marui et al., 2002). Moreover, similar
to DLB, PD patient data demonstrates that these individuals
experience first locomotor symptoms once 50–60% of DA
striatal terminals have already been lost, while the loss of DA
neurons in the SN is believed to be only around 30% (reviewed
in Burke and O’Malley, 2013). These observations have been
independently confirmed by positron emission tomography; PD
patients in early stages of the disease show extensive axonal
damage and loss of nigrostriatal pathway connectivity (Caminiti
et al., 2017). This data suggests that α-Syn pathology is abundant
in presynaptic terminals and axons, in line with the observation
that its normal localization is predominantly in presynaptic
terminals (Figure 3). Yet little is known how early accumulation
of toxic α-Syn species impairs synaptic homeostasis and function,
ultimately leading to DA neurodegeneration in PD.
THE JANUS FACE OF PRESYNAPTIC
α-SYN: PHYSIOLOGY AND PATHOLOGY
Synapses are the intercellular junctions between a presynaptic
neuron and a postsynaptic cell (Südhof, 2012). They are used
to transmit signal between neurons in the CNS via exocytosis
of neurotransmitter allowing an organized flux of information
through the brain (Lepeta et al., 2016). Synapses are composed of
a presynaptic terminal, synaptic cleft and postsynaptic terminal
which require a complex and tight regulation for proper
neurotransmission to occur (Figure 4; Südhof and Rizo, 2011;
Südhof, 2012).
The presynaptic nerve terminal is a specialized secretory
machinery that releases neurotransmitters by synaptic vesicle
(SV) exocytosis in response to an action potential. It is at the
presynaptic terminal where α-Syn is hypothesized to play its
physiological or pathological role (Katz, 1969; Chandra et al.,
2005; Burré, 2015). By receiving an action potential, calcium
(Ca2+) channels open, thereby allowing influx of Ca2+ into
the presynaptic terminal (Südhof, 2013b). This Ca2+ influx
promotes the assembly of a molecular machinery composed
mainly of the Ca2+ sensor synaptotagmin and the soluble
NSF-attachment protein receptor (SNARE) complex, including
VAMP-2, SNAP-25, and Syntaxin-1 (Südhof, 2013a). Ultimately,
this molecular machinery will trigger SV trafficking from the
closest pool, the readily releasable pool (RRP), to be tethered,
docked and fused to the presynaptic plasma membrane at a
defined region of the presynaptic terminal called the active
zone (AZ) (Figure 4), for subsequent release of neurotransmitter
in the synaptic cleft (Südhof, 2000, 2012, 2013b; Alabi and
Tsien, 2012). In addition to the SNARE complex, a subfamily
of highly conserved small GTPases called Rab are implicated in
intracellular trafficking of vesicles and the recruitment of SV in
the AZ (Binotti et al., 2016).
The AZ matrix is composed of several proteins including
RIM, ELKS (also known as ERC/CAST/Rab6IP2), Munc13,
Bassoon/Piccolo, Rim-BP, and Liprin-α (Schoch and
Gundelfinger, 2006; Südhof, 2012; Wang et al., 2016). The
AZ is a highly organized structure restricted to the plasma
membrane region, opposite to the postsynaptic density marked
by postsynaptic density protein 95 (PSD95). Functionally, AZ
proteins dock SVs to be fused with the plasma membrane and
release their neurotransmitter content into the synaptic cleft
(Figure 4; Wang et al., 2016). After exocytosis, the SV membrane
is retrieved from the synaptic cleft by endocytosis, either via
clathrin-dependent slow or clathrin-independent fast modes of
endocytosis (Saheki and De Camilli, 2012). The SV are locally
loaded with neurotransmitter, hence being recycled to allow
another round of exo-endocytotic membrane cycling (Südhof,
2004; Gross and von Gersdorff, 2016). This mechanism allows
the neurons to sustain a high firing rate without depletion of the
SV pools (Saheki and De Camilli, 2012; Gross and von Gersdorff,
2016).
Deficiencies in synaptic transmission have been observed
in response to both knock down or overexpression of α-Syn,
suggesting that it has a role in the regulation of neurotransmitter
release, synaptic function and homeostasis (Box 1) (Kahle et al.,
2000; Lee et al., 2008; Zhang et al., 2008; Lashuel et al.,
2013; Vargas et al., 2017). Under physiological conditions, α-
Syn is found at the presynaptic terminal (Maroteaux et al.,
1988) and exists in a dynamic equilibrium between a soluble
and a membrane-bound state (Burré, 2015). Specifically, α-Syn
is localized to presynaptic boutons due to its preference for
membranes with high curvature (Middleton and Rhoades, 2010;
Jensen et al., 2011). Despite its known presynaptic localization,
the physiological functions of α-Syn remain poorly understood.
In the following sections, we will discuss the evidence for
physiological and pathological roles of α-Syn in the presynaptic
terminal.
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FIGURE 4 | The presynaptic exo-endocytotic cycle regulating neurotransmitter release is specifically affected in α-Syn-related synaptopathies. Upon an incoming
action potential, calcium (Ca2+) channels become permeable to Ca2+ entry in the presynaptic terminal. This activates a molecular machinery including the SNARE
complex proteins that recruit synaptic vesicles (SV) from the proximal resting and recycling (RP) pools via trafficking and tethering to form the readily releasable pool
(RRP). After docking and priming, RRP vesicles undergo SNARE-mediated membrane fusion at the active zone (AZ, shaded area), ultimately leading to
neurotransmitter (NT) release into the synaptic cleft. After exocytosis, the SV membrane is retrieved to the presynaptic terminal via endocytosis, to be filled with NT (NT
uptake) and re-enter the exo-endocytotic cycle, thereby granting the neuron its ability to sustain high firing rates. PSD95, postsynaptic density protein-95.
α-Syn Affects Synaptic Vesicle Pools and
Their Trafficking in the Presynaptic
Terminal
The SV pools can be divided accordingly to the number of
SVs and distance from the AZ (Südhof, 2000; Alabi and Tsien,
2012). The RRP is the closest in proximity to the AZ, containing
the smallest number of vesicles and holding the highest fusion
probability. The recycling pool (RP) is located above the RRP
and has three times more vesicles than the RRP. The RP
repopulates vacancies at the RRP which are often rate-limiting
during persistent activity and along with the RRP compose the
total recycling pool (Alabi and Tsien, 2012). Finally, the most
distal SV pool is called the resting pool, this is the largest pool
of SVs that remain unreleased even after prolonged synaptic
stimulation (Figure 4; Südhof, 2000; Alabi and Tsien, 2012).
α-Syn has been shown to be associated with the recycling
pool of SVs and its proteins. Depletion of α-Syn, through the
use of antisense oligonucleotides, induces a decrease in the
availability of reserve synaptic vesicle pool in primary cultured
hippocampal neurons (Murphy et al., 2000). α-Syn knockout
(KO) mice revealed a striking deficiency of undocked vesicles
without affecting docked vesicles at the RRP (Cabin et al., 2002).
In addition, the refilling of the docked vesicles by the resting
pool after depletion was slower in the synapses of mice lacking
α-Syn (Cabin et al., 2002). Together this data strongly supports
a role of α-Syn in SV trafficking at the presynaptic terminal by
modulating vesicular dynamics and maintaining the homeostasis
of vesicle RPs.
Overexpression of wild type and mutant α-Syn in Chromaffin
and PC12 cells revealed inhibited evoked neurotransmitter
release (Larsen et al., 2006). This inhibition was attributed to
a smaller population of RRP, suggesting that α-Syn inhibits the
vesicle “priming” step which is the intermediate step between
vesicle docking and fusion of synaptic vesicles at the AZ (Larsen
et al., 2006). Furthermore, overexpression of wild type α-Syn
to similar levels observed in PD patients with duplication
and triplication of the SNCA gene, inhibited neurotransmitter
exocytosis by affecting the size of the RP (Nemani et al., 2010;
Scott and Roy, 2012).
Interestingly, ultrastructural analysis of the synapse in mice
overexpressing human wild type α-Syn demonstrated the total
number of SVs in the presynaptic terminal was not altered.
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Instead, these animals displayed reduced numbers of SVs at a
close proximity to the AZ, whereas numbers of SVs at greater
distances were increased (Nemani et al., 2010). Furthermore,
this study concluded that exocytotic deficits caused by α-Syn
overexpression were not only caused by reduced size of the RP,
but also due to disturbances of SV reclustering after endocytosis
(Nemani et al., 2010). These findings demonstrate high levels of
α-Syn can trigger impairment of exocytosis via alteration of SV
pools in absence of neurodegeneration.
The SNARE Complex Related to α-Syn
Function and Dysfunction
The SNARE proteins are crucial to allow SVs to fuse with
the plasma membrane at the AZ to release neurotransmitter
(Südhof and Rizo, 2011). The subsequent exocytosis requires the
assembly of presynaptic machinery proteins thousands of times
per minute. During each episode, the SNARE complex assembly
and disassembly gives rise to extremely reactive unfolded SNARE
protein intermediates, exposing the presynaptic terminal to
potentially vulnerable activity-dependent degeneration (Burré
et al., 2010; Südhof and Rizo, 2011). α-Syn has been shown to
act as a chaperone to promote SNARE complex assembly and
to support its folding through direct binding to VAMP-2 and
phospholipids on synaptic vesicles (Burré et al., 2010).
In line with these observations, α-Syn overexpression is
able to rescue neurodegeneration observed in CSPα KO mice
by chaperoning the assembly of the SNARE complex, while
concomitant knockout of α-Syn exacerbates the CSPα KO
phenotype (Chandra et al., 2005). CSPα acts as a chaperone
of the SNARE complex by supporting the functional ability of
SNAP-25 to engage in a complex with Syntaxin-1 and VAMP-
2 (Figure 5A; Sharma et al., 2011). The chaperone function
of CSPα within the SNARE complex is shared with α-Syn,
however the mechanisms differ. α-Syn binds to VAMP-2 via its
C-terminal (Burré et al., 2010) which appears to be essential for α-
Syn mediated neuroprotection because the A30P α-Syn mutant,
which is deficient in its ability to bind to membranes, failed
to rescue CSPα KO mice (Chandra et al., 2005). This role of
native α-Syn in assisting SNARE complex assembly contributes
to clustering of SV at the AZ (Figure 5A). Besides functioning
as chaperone, α-Syn is also important for maintenance and
redistribution of the SNARE complex which is directly implicated
in neurotransmitter release, including dopamine (Burré et al.,
2010; Diao et al., 2013).
The synaptic accumulation of oligomers and aggregated α-
Syn and its interaction with components of the presynaptic
machinery, such as SNARE proteins, is likely to underlie at
least one of the pathological mechanisms that lead to synaptic
dysfunction in the early stages of PD (Box 1) (Figure 5B). In
support of this hypothesis, studies in vitro have demonstrated
large α-Syn oligomers bind to the N-terminal domain of VAMP-
2, thus blocking SNARE-mediated vesicle docking (Choi et al.,
2013), which in vivo could be directly linked to impaired
exocytosis of neurotransmitters in overexpression models of α-
Syn. Interestingly, another in vitro study by Lai and co-authors
revealed that levels and different toxic species of α-Syn inhibit
synaptic vesicle docking via distinct mechanisms (Lai et al.,
2014). These data suggest that α-Syn may form various types of
oligomeric states with different toxicity, as has been shown for
aggregated tau protein in tauopathies (Goedert, 2015). Moreover,
Scott and colleagues showed that cultured hippocampal neurons
from transgenic animals overexpressing human α-Syn displayed
absence of endogenous synaptic proteins, including the SNARE
complex protein VAMP-2 and SV proteins amphiphysin
and synapsin-1 (Scott et al., 2010). Neurons overexpressing
fluorescent human α-Syn demonstrated marked deficits in
neurotransmitter release, in addition to reduced numbers of SVs,
and enlargement of the remaining SVs (Scott et al., 2010). Studies
investigating levels of synaptic proteins belonging to the SNARE
complex in PD, PD with dementia (PDD) and DLB post-mortem
samples also reported misregulation of proteins belonging to the
SNARE complex (Kramer and Schulz-Schaeffer, 2007; Dijkstra
et al., 2015; Bereczki et al., 2016, 2018). Moreover, an in vitro
model of α-Syn toxicity, primary neuronal cultures exposed to
preformed α-Syn fibrils exhibited loss of the SNARE complex
proteins VAMP2 and SNAP-25, as well as the SV proteins CSPα
and synapsin-2 (Volpicelli-Daley et al., 2011). Volpicelli-Daley
and colleagues further investigated the impact of accumulation
of these preformed α-Syn fibrils in neural network activity.
Interestingly, they found that impaired hippocampal network
activity occurred much earlier than the detected reduction in
synaptic protein levels, suggesting that α-Syn pathology can have
a major impact on the coordination of neuronal communication
and connectivity (Box 1) (Volpicelli-Daley et al., 2011).
Conversely, a mouse model expressing human truncated α-
Syn leading to α-Syn aggregates did not show changes in levels of
synaptic proteins but rather caused age-dependent redistribution
and accumulation of SNAP-25, Syntaxin-1, and VAMP-2 in
the striatum accompanied by an age-dependent reduction in
dopamine release (Garcia-Reitböck et al., 2010). SNARE proteins
were also redistributed in the striatum and external globus
pallidus of early-onset PD patients (Garcia-Reitböck et al., 2010).
Taken together, evidence from transgenic mouse models and PD
patients demonstrate that accumulated α-Syn alters the levels
and/or localization of SNARE proteins at the presynaptic nerve
terminal. These findings suggest that α-Syn accumulation causes
a toxic gain of function phenotype at the synapses, thus impairing
their function and connectivity.
Accumulated α-Syn Impairs Rabs and Their
Function in Synaptic Vesicle Trafficking
The trafficking of synaptic vesicles within the presynaptic
terminal is vital to recruit them from the SV pools into the active
zone (Figure 4; Südhof, 2000). This is a complex process that
involves a significant number of proteins and must be tightly
controlled (Takamori et al., 2006; Südhof, 2013b). Amongst the
proteins involved in presynaptic vesicle trafficking, a superfamily
of highly conserved small GTPases called Rab act as the master
regulator of intracellular trafficking processes, including vesicle
budding and uncoating, motility, tethering and fusion (reviewed
in Kelly et al., 2012). Rab3A protein, for instance, is abundant in
SV with its activity regulated by two effectors: Rabphilin and RIM
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FIGURE 5 | Onset of α-Syn-mediated synaptopathies is likely related to impaired presynaptic active zone function and defective neurotransmitter release. (A) In
healthy subjects, the presynaptic terminal of a neuron comprises a functional exo-endocytotic cycling machinery, including vesicle pools, SNARE complex proteins
and the active zone (AZ) which is formed of a dense network of proteins called AZ matrix. The AZ matrix is the site of action for synaptic vesicle tethering, docking and
membrane fusion for neurotransmitter release which is mediated by SNARE complex proteins including VAMP-2, SNAP-25, and Syntaxin-1. This process is directed
and co-chaperoned by CSP and α-Syn toward the AZ, a scaffold that includes ELKS/CAST proteins, the Drosophila homolog of Bruchpilot (BRP). BRP mutants have
been shown to cause dramatic reduction of nerve-evoked transmission. Maintenance of BRP within the AZ matrix scaffold is dependent on direct interaction with
NMNAT which protects BRP against ubiquitin (Ub)-mediated degradation and activity-induced neurodegeneration. (B) In PD patients, presynaptic neuronal terminals
accumulate toxic oligomers and protofibrils of α-Syn that interfere with the exo-endocytotic cycling machinery, including AZ proteins NMNAT and BRP/ELKS/CAST
(enlarged in C). (C) Disease-related downregulation of NMNAT leads to ubiquitination and degradation of BRP/ELKS/CAST, resulting in the gradual decrease and
eventual dissolution of the AZ matrix, ultimately causing impaired synaptic transmission and α-Syn-mediated synaptopathy. However, it is currently unknown (doted
red lines) whether toxic forms of α-Syn directly or indirectly interfere with NMNAT and/or BRP/ELKS/CAST, thereby causing the AZ to lose its physiological function.
(for Rab3 interactingmolecules; Shirataki et al., 1993;Wang et al.,
1997). Mechanistically, Rab3A is part of a complex formed by the
AZ proteins Munc13 and RIM, designed to capture SVs for final
membrane attachment called tethering and to prepare them for
synaptic release (Wang et al., 1997; Dulubova et al., 2005).
α-Syn was shown to interact and cause defects in vesicular
trafficking pathways including those taking place at the
presynaptic terminal of neurons (Dalfó et al., 2004; Gitler et al.,
2008; Abeliovich and Gitler, 2016). In line with this observation,
several members of Rab GTPase family have been identified
to interplay with α-Syn (Chutna et al., 2014; Gonçalves et al.,
2016). This interaction has also been observed in post-mortem
tissue of DLB and MSA patients with LB pathology where α-Syn
abnormally interacts with Rab3A. In addition, α-Syn aggregates
were found to trap Rab3A and prevent its interaction with
rabphilin, thus suggesting that exocytosis and neurotransmitter
release are affected in Lewy body diseases (Dalfó et al., 2004).
Further studies have proposed that Rab3A regulates membrane
association of α-Syn in a GTP-dependent manner (Chen et al.,
2013), implying functional integration of α-Syn into Rab proteins
cycle between the cytosol and the membrane-bound state, and
hence into the SV cycle (Bendor et al., 2013).
These functional interactions are further supported in a
Caenorhabditis elegansmodel overexpressing wild type human α-
Syn which revealed that manipulating levels of Rab3A, Rab1 and
Rab8A significantly rescued α-Syn mediated loss of DA neurons
(Gitler et al., 2008). Similar effects were seen in rat midbrain
cultures transfected with A53Tmutant α-Syn (Gitler et al., 2008).
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α-Syn mediated neurotoxicity was hypothesized to be caused by
α-Syn affecting transport of SV via direct interaction with the
trafficking machinery (Gitler et al., 2008). Furthermore, studies
in Drosophila melanogaster suggest that Rab3 is also involved in
the formation of the AZ architecture, however the mechanisms
remain unknown (Chen et al., 2015; Bae et al., 2016).
The Active Zone Matrix and α-Syn
The docking and fusion of SVs are restricted to the active
zone, demonstrating that the AZ is essential to translate
an incoming action potential into neurotransmitter release
(Figure 4; Schoch and Gundelfinger, 2006; Südhof, 2012; Wang
et al., 2016). The AZ is a highly conserved specialized
presynaptic scaffold characterized by a dense network of
proteins called AZ matrix. In mammals, this matrix includes
RIM, ELKS, Munc13, Bassoon/Piccolo, Rim-BP, and Liprin-α
(Schoch and Gundelfinger, 2006; Südhof, 2012; Wang et al.,
2016). Furthermore, additional proteins are present but not
restricted to the AZ, including SNAREs, ion channels, receptors,
cytoskeletal proteins and adhesion molecules (Wang et al.,
2016). Considering the high number of proteins constituting
the AZ, it is important for this presynaptic compartment to
be tightly regulated according to synaptic activity for reliable
neurotransmitter release to occur (Körber and Kuner, 2016).
Although a large amount of evidence indicates that
accumulation of α-Syn at the presynaptic terminal causes
reduction of proteins involved in synaptic transmission, to our
knowledge, α-Syn has not been shown to directly interact with
AZmatrix proteins under normal conditions. In addition to that,
only a few studies have explored the pathological role of α-Syn
affecting proteins associated with the AZ. Mantin and colleagues
reported mice overexpressing human mutant A53T α-Syn which
showed abnormal inclusions of α-Syn within dendrites and in
the presynaptic AZ (Martin et al., 2006). Furthermore, a recent
ultrastructural study by Kohl and colleagues utilized a bacterial
artificial chromosome (BAC) rat model expressing full-length
human SNCA gene. These transgenic rats displayed extended
AZs in synapses of hippocampal CA3 neurons compared to
non-transgenic animals, a phenotype that was accompanied by
reduction of the postsynaptic density. However, PSD95 levels
were found to be upregulated in the dentate gyrus/CA3 regions
in combination with downregulation of synapsin1 and RIM3
(Kohl et al., 2016). This study suggests that α-Syn does not only
compromise the presynaptic but also postsynaptic terminals by
altering both RIM3 and PSD95. The RIM protein family is an
essential regulator of active zone function (Mittelstaedt et al.,
2010; Südhof and Rizo, 2011). Another AZ protein called Piccolo
was shown to be absent in a significant number of synaptic
boutons in a model overexpressing α-Syn (Scott et al., 2010).
Piccolo along with Bassoon are specific to the vertebrate AZ and
do appear to have a major function in guiding SVs to the AZ
(Mukherjee et al., 2010; Südhof, 2012).
Since α-Syn has been demonstrated to accumulate at the AZ
(Martin et al., 2006), it is reasonable to hypothesize that AZ
matrix proteins become dysfunctional over time. Moreover, α-
Syn accumulation in the AZ may jeopardize a compensatory
activity of AZ proteins to overcome the upstream deleterious
effects caused by toxic α-Syn, such as alterations of SV
pools, SNAREs, and intracellular trafficking that together lead
to impaired neurotransmitter exocytosis (Larsen et al., 2006;
Nemani et al., 2010; Scott et al., 2010; Janezic et al., 2013).
Furthermore, the accumulation of toxic α-Syn species in the AZ
triggers the proteasome system to degrade not only α-Syn but
also AZ matrix components, the levels of which are normally
regulated by proteasome activity (Wang et al., 2017).
Work carried out in Drosophila melanogaster has provided
at least one mechanistic pathway by which the presynaptic
AZ is sustained under disease-related stress (Figure 5). The
maintenance of the AZ structure against activity-induced
degeneration is provided by a chaperone called Drosophila
nicotinamide mononucleotide adenylyltransferase (dNMNAT)
(Zang et al., 2013). This neuroprotective effect is provided
through NMNAT, which protects the AZ protein Bruchpilot
(BRP), a homolog of mammalian ELKS/CAST proteins, from
ubiquitination and subsequent degradation. However, it is not
known whether high levels and/or toxic α-Syn species, such as
oligomers and fibrils, exert a toxic gain of function onto the AZ
by interfering with NMNAT function (Figures 5B,C).
Unlike Drosophila that only encodes one NMNAT homolog,
mammals possess three different NMNAT orthologues that
are distinguishable by their differential localization within
subcellular compartments (Brazill et al., 2017). NMNAT1 is a
nuclear protein, NMNAT2 is localized to the Golgi apparatus
and NMNAT 3 is predominantly mitochondrial (Ali et al., 2013).
NMNATs are classically known for their enzymatic function
of catalyzing NAD+ synthesis, which is an essential cofactor
in many cellular processes including oxidative reactions and
transcriptional regulation (Lau et al., 2009). NMNAT is also able
to act as a molecular chaperone (reviewed in Ali et al., 2013),
which is critical for neuronal homeostasis and protection against
cellular stress (Ali et al., 2012; Ocampo et al., 2013; Rallis et al.,
2013). However, this role does not require the enzymatic function
of NMNAT, as the inactive form of dNMNAT was able to protect
Drosophila photoreceptors against activity-induced degeneration
(Zhai et al., 2006, 2008).
Consistent with the role of NMNAT as a neuronal
maintenance factor, it has been shown that NNMAT2, which
is enriched in synaptic terminals and SVs, is downregulated
in several degenerative disorders. These include PD, AD,
Huntington’s disease (HD) and frontotemporal lobar
degeneration with ubiquitin- and TDP-43-positive inclusions
(FTLD-TDP) (Ali et al., 2013). NMNAT2 alterations were also
found in a mouse model of tauopathy expressing mis-sense
mutation P301L, found in some frontotemporal dementia
and parkinsonism linked to chromosome 17 (FTDP-17)
cases (Ljungberg et al., 2012). The neuroprotective effects of
mammalian NMNAT2 has been explored in more detail in
axonal degeneration, where loss of NMNAT2 is considered to be
a physiological stimulus in severed axons and their subsequent
Wallerian degeneration (Gilley and Coleman, 2010). In line with
this notion, NMNAT2 overexpression was found to delay injury-
induced axonal degeneration in zebrafish (Feng et al., 2010) and
to protect mice against tauopathy-induced neurodegeneration
(Ljungberg et al., 2012).
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Accumulated α-Syn Affects Synaptic
Vesicle Endocytosis
In order to sustain high rates of synaptic transmission without
depleting the supply of SVs, neurons have to rely on efficient
endocytic recycling of SV membranes (Figure 4; Saheki and
De Camilli, 2012). The synuclein family is required for SV
endocytosis (Vargas et al., 2014). Using a triple synuclein
KO mouse model, Vargas and colleagues demonstrated that
synucleins are required for fast and efficient kinetics of early
steps of SV endocytosis, membrane bending and cargo selection
(Vargas et al., 2014). Fundamentally, the impaired endocytic
process observed in the triple KO mouse could be re-established
by individual expression of α-, β-, or È-Syn, demonstrating they
are functionally redundant in the endocytic process (Vargas et al.,
2014).
Rab5, which has been localized to the early endosome and
is implicated in the regulation of neuronal endocytosis in
association with Rabaptin-5 (Stenmark et al., 1994; Cataldo
et al., 2000), appears to play a role in the internalization of
exogenous α-Syn. Overexpression of constitutively active Rab5 or
its effector Rabaptin-5 in cultured neurons lead to the formation
of intracellular inclusions resembling Lewy bodies (Sung et al.,
2001). More recently, a study revealed that high levels of α-Syn
promotes its interaction with dynein, a retrograde motor protein,
inducing a significant increase in activated levels of Rab5 and
Rab7, both key regulators of the endocytic process (Fang et al.,
2017).
Under intense electric stimulation, overexpression of wild
type α-Syn in lamprey nerve terminals caused loss of SVs
and an expanded plasma membrane which pointed toward
impaired vesicle recycling (Busch et al., 2014). However, this
endocytic deficit was not observed when low stimulation was
applied. Interestingly, overexpression of mutant A30P α-Syn,
with a disrupted N-terminal that greatly impairs its binding to
phospholipids and disrupt the α-helical conformation, showed
very little effect on vesicle recycling. Therefore, Busch and
colleagues concluded that synaptic endocytic failure could only
be visualized when high synaptic activity is in place and
under proper folding of α-Syn N-terminal α-helix (Busch
et al., 2014). Corroborating these findings, overexpression of
mutant human A53T α-Syn, but not A30P α-Syn, at the
calyx of Held terminals in mice was also shown to cause
impairment of slow and rapid endocytosis, and restoration of
the RRP (Xu et al., 2016). These studies endorse the role of α-
Syn in membrane curvature formation and stabilization, and
consequently for endocytosis (Pranke et al., 2011; Busch et al.,
2014).
α-Syn Related Presynaptic Deficits
Converge in Dopaminergic Neurons
Under physiological conditions, native soluble α-Syn is involved
in several steps in the presynaptic terminal that are required
to trigger exocytosis upon activation by an action potential
(Burré, 2015). However, these steps are not exclusively regulated
by α-Syn. Under pathological conditions, the presence of toxic
α-Syn species such as oligomers and amyloid fibrils, triggers
the misregulation of several synaptic proteins (Table 1), leading
to functional impairment of the presynaptic terminal in both
animal models and PD patients (Figure 5). These alterations
at the presynapse have been shown to be progressive and
selective to dopaminergic neurons, at least in mouse models
(Volpicelli-Daley et al., 2011; Janezic et al., 2013). Thus, upon
α-Syn accumulation, DA neurons show reduced firing rates, a
phenotype that positively correlates with behavior impairment,
ultimately followed by degeneration of these neurons (Janezic
et al., 2013).
A similar sequence of events whereby presynaptic deficits
precede neuronal loss are also recapitulated in induced
pluripotent stem cells (iPSCs) derived from PD patients that
harbor the A53T α-Syn mutation. Kouroupi and colleagues
observed a significant downregulation of genes coding for
presynptic proteins in comparison to controls (Kouroupi et al.,
2017). Strikingly, A53T α-Syn iPSCs cells exhibited thinner,
less fasciculated neuronal processes that were accompanied by
a 27% reduction in the number of synaptic contacts. The
deleterious effects caused by overexpression of human α-Syn
were also observed in Drosophila which identified reduced
synaptic connectivity between DA neurons and Kenyon cells
even before the onset of motor abnormalities (Riemensperger
et al., 2013).
Together this data suggests that there is a potential
direct association, between α-Syn accumulation and dopamine
metabolism, which in turn makes DA neurons especially
vulnerable to cellular stress and subsequent neurodegeneration.
Indeed, several recent findings support this hypothesis, which
could shed light onto the pathogenic mechanisms underlying DA
neuron-specific cell death in PD.
α-SYN AND DOPAMINE: A DANGEROUS
LIAISON
The loss of dopaminergic neurons in the substantia nigra
along with α-Syn enriched Lewy body inclusions are the main
histopathological hallmarks of PD (Lees et al., 2009). DA
neurons are thought to be the most vulnerable cell type in
PD, which led to several hypotheses attempting to explain
the underlying mechanisms. One of these is related to the
high-energy requirement of DA neurons due to their poorly
myelinated axonal arborisation which is orders of magnitude
larger than any other neuronal cell type (Pissadaki and Bolam,
2013). This hypothesis predicts that any disturbance inducing
a negative energy balance would be especially dangerous to DA
neurons, placing them at high risk in case of energy failure, such
as mitochondrial dysfunction, which has been shown to play an
important role in PD (Lin and Beal, 2006).
Although energy balance contributes to the vulnerability of
DA neurons, regulation of dopamine levels at the synaptic
terminals is thought to be vital for DA neuron susceptibility
observed in PD (Lotharius and Brundin, 2002b). Accordingly,
α-Syn has been implicated as a key regulator of dopamine
homeostasis (Abeliovich et al., 2000; Venda et al., 2010).
The activity of the rate-limiting enzyme tyrosine hydroxylase
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(TH) responsible for producing dopamine through conversion
of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA), is
negatively regulated by increased concentration of α-Syn in vitro
(Perez et al., 2002). As a result, reduced levels of dopamine were
observed in cell culture transfected with A53T mutant α-Syn
(Perez et al., 2002).
In line with these findings, reduced TH activity was found in
mouse models overexpressing α-Syn (Masliah et al., 2000; Kirik
et al., 2002). Mechanistically, α-Syn decreases TH activity by
reducing its phosphorylation in vitro (Perez et al., 2002; Peng
et al., 2005) as TH is activated by phosphorylation of seryl
residues in the TH regulatory domain (Alerte et al., 2008). In
turn, by silencing α-Syn in MN9D cells, increased TH activity
and dopamine biosynthesis were observed (Liu et al., 2008). In
addition to the ability of α-Syn to regulate TH activity, work
performed by Tehranian and colleagues demonstrated that α-Syn
can interact with L-aromatic amino acid decarboxylase (AADC)
and can reduce its activity (Tehranian et al., 2006). AADC acts
in the last step of dopamine synthesis by converting L-DOPA to
dopamine (Tehranian et al., 2006).
α-Syn does not only modulate the activity of enzymes
responsible for dopamine synthesis, but it also impairs transport
and uptake of dopamine by altering the activity of the
vesicular monoamine transporter 2 (VMAT2) and the dopamine
transporter (DAT), respectively. VMAT2 is responsible for
dopamine uptake from the cytoplasm into SV (Lotharius and
Brundin, 2002b). DAT transports dopamine from the synaptic
cleft back into the cytoplasm is the primary mechanism and
possibly the most important regulator of extracellular dopamine
concentrations (Vaughan and Foster, 2013). Lundblad and
colleagues showed that unilateral overexpression of human wild
type α-Syn in the SN of adult rats caused 50% reduction
in dopamine reuptake without axonal damage 10 days after
exposure (Lundblad et al., 2012). Over time, dopamine reuptake
was further decreased in the striatum, followed by axonal swelling
and dystrophic axons in the presence of α-Syn aggregates
and a profound 70% reduction in dopamine release upon
chemical pulse with potassium chloride (Lundblad et al., 2012).
Additionally, α-Syn was shown to interact with DAT and in turn
to form complexes via the carboxyl-terminal tail of DAT and
the NAC domain of α-Syn (Lee et al., 2001). This interaction
and complex formation reduced DAT activity due to impairment
of dopamine reuptake from the synaptic cleft (Wersinger and
Sidhu, 2003; Wersinger et al., 2003), suggesting that α-Syn
accumulation causes a vicious cycle of impaired VMAT2 and
DAT function.
Consistent with this notion, Bellucci et al. showed that
mice expressing the truncated α-syn120 exhibited marked
redistribution of DAT/α-Syn complexes in the striatum and
the SN (Bellucci et al., 2011). These findings suggest that
α-Syn acts as a synaptic modulator of DA in early PD
pathogenesis by regulating the subcellular distribution of key
proteins such as DAT (Bellucci et al., 2011). DAT has also
been reported to be absent in the putamen of PD patients
(Seeman and Niznik, 1990). Interestingly, VMAT2 was shown
to be incorporated into Lewy bodies of SN neurons in PD
patients (Yamamoto et al., 2006). Moreover, profound defects in
VMAT2 were also observed in synaptic vesicles isolated from
post-mortem brain tissue of PD patients, including reduction
in vesicular uptake and the binding ability of VMAT2 (Pifl
et al., 2014). These findings are in agreement with previous
studies showing that increased levels of α-Syn inhibit VMAT2
activity, ultimately increasing cytosolic levels of dopamine (Guo
et al., 2008). As a consequence, dysregulation of dopamine
transport caused by impaired DAT and VMAT2 activity will
lead to altered levels of dopamine (Lotharius and Brundin,
2002b; Nutt et al., 2004). Dopamine by itself is a risk factor
for dopaminergic neurodegeneration; it is highly sensitive to
spontaneous degradation and to produce quinone as well as
other reactive oxygen species until it is sequestered into vesicles
(Lotharius and Brundin, 2002a,b; Xu et al., 2002; Caudle et al.,
2007).
This data suggests an intricate and potentially direct interplay
between α-Syn and dopamine that directly contributes to
functional deficits of DA neurons. In support of this, Mor
et al. recently demonstrated that dopamine promotes α-
Syn oligomerisation in vivo and that disrupting the ability
of dopamine to stabilize or modify α-Syn oligomers was
sufficient to rescue dopamine-mediated toxicity (Mor et al.,
2017). These results recapitulate in vitro data revealing the
ability of dopamine to trigger formation of α-Syn oligomers
(Choi et al., 2013). This cooperative toxicity of α-Syn and
dopamine was also recapitulated in C. elegans (Mor et al.,
2017). Furthermore, a corresponding mouse model revealed
early mild synaptic defects in the striatum without degeneration
of cell bodies; however, by 5 months post-injection, the mice
exhibit a severe loss of dopaminergic nerve terminals (−62%
VMAT2 and −55% DAT) as compared to only 25% loss of
dopaminergic neurons (Mor et al., 2017). These results reinforce
the hypothesis that α-Syn mediated early dopamine imbalance
at synaptic terminals is the initiating event which in turn
triggers synaptic and axonal dysfunction, subsequently leading to
degeneration of nigrostriatal pathways and DA neuron-specific
cell death.
CONCLUSIONS
Studies in PD-related animal models and post-mortem patient
material demonstrate that soluble oligomers and aggregating
protofibrils of α-Syn accumulate in synapses and axons prior
to the onset of disease symptoms. These accumulating toxic
α-Syn species impair synaptic compartments and presynaptic
processes required for neuronal communication, including
maintenance of SV pools, SV trafficking, tethering, docking,
priming and fusion of SV within the plasma membrane at the
active zone. The resulting synaptopathy phenotypes manifest
prior to dopaminergic neurodegeneration, hence reinforcing
the hypothesis that onset and evolution of PD progress in
a dying back-like manner, from initial dysfunction at the
synapse and impairing axonal connections, to eventual neuronal
cell body death. Although α-Syn is expressed throughout the
brain and enriched at presynaptic terminals, DA neurons are
most susceptible to toxic effects exerted by accumulating and
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dysfunctional α-Syn. This fatal attraction is likely related to
α-Syn regulating dopamine levels in two distinct manners.
First, α-Syn is a negative modulator of dopamine synthesis
by interplay with the rate-limiting enzyme TH and AADC.
Second, α-Syn disrupts VMAT2 and DAT activity and their
function in regulating dopamine levels in the synaptic terminal.
In turn, dysregulated dopamine levels fuel the formation
of soluble α-Syn oligomers that are considered to be the
most toxic species. This fatal interplay and its ensuing
vicious cycle of dopamine and α-Syn interference is likely
the starting point driving synaptic dysfunction and impaired
neuronal communication observed in the early, prodromal stages
of PD.
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